JP2023522520A5 - - Google Patents

Info

Publication number
JP2023522520A5
JP2023522520A5 JP2022538834A JP2022538834A JP2023522520A5 JP 2023522520 A5 JP2023522520 A5 JP 2023522520A5 JP 2022538834 A JP2022538834 A JP 2022538834A JP 2022538834 A JP2022538834 A JP 2022538834A JP 2023522520 A5 JP2023522520 A5 JP 2023522520A5
Authority
JP
Japan
Prior art keywords
hvem
human
antibody
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522520A (ja
JP7681025B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2020/050817 external-priority patent/WO2021133170A1/en
Publication of JP2023522520A publication Critical patent/JP2023522520A/ja
Publication of JP2023522520A5 publication Critical patent/JP2023522520A5/ja
Application granted granted Critical
Publication of JP7681025B2 publication Critical patent/JP7681025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538834A 2019-12-24 2020-12-24 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用 Active JP7681025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19219684 2019-12-24
EP19219684.8 2019-12-24
PCT/NL2020/050817 WO2021133170A1 (en) 2019-12-24 2020-12-24 Anti-human hvem (tnfrsf14) antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023522520A JP2023522520A (ja) 2023-05-31
JP2023522520A5 true JP2023522520A5 (https=) 2025-04-08
JP7681025B2 JP7681025B2 (ja) 2025-05-21

Family

ID=69061152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538834A Active JP7681025B2 (ja) 2019-12-24 2020-12-24 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用

Country Status (10)

Country Link
US (1) US12503516B2 (https=)
EP (1) EP4081541A1 (https=)
JP (1) JP7681025B2 (https=)
KR (1) KR20220128363A (https=)
CN (1) CN115087672A (https=)
AU (1) AU2020414265A1 (https=)
BR (1) BR112022012725A2 (https=)
CA (1) CA3162656A1 (https=)
MX (1) MX2022007855A (https=)
WO (1) WO2021133170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265639A2 (en) * 2020-12-15 2023-10-25 Medytox Inc. Anti-hvem antibody, and composition and method associated with same
US20240317871A1 (en) * 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
CN116715769B (zh) * 2022-05-26 2024-06-25 四川大学 抗hvem抗体、制备方法及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US8188232B1 (en) * 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
WO2010006071A1 (en) * 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006090385A2 (en) * 2005-02-22 2006-08-31 Ramot At Tel-Aviv University Ltd. Protease inhibitors and method of screening thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008146101A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
EP3002296B1 (en) * 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
TWI427085B (zh) * 2011-11-02 2014-02-21 國立成功大學 活化纖維蛋白溶酶原之抗體、其用途以及含有其之製劑
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
US12036242B2 (en) * 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020095249A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
BR112021021645A2 (pt) * 2019-04-29 2021-12-21 4C Biomed Ltd Anticorpos anti-hvem e uso dos mesmos.
JP7716393B2 (ja) * 2019-10-04 2025-07-31 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用

Similar Documents

Publication Publication Date Title
AU2020201069B2 (en) Anti-PD1 antibodies and their use as therapeutics and diagnostics
AU2024201607A1 (en) Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
AU2017317227B2 (en) Anti-Tim-3 antibodies and use thereof
TWI734879B (zh) 抗ox40抗體及其用途
US10618962B2 (en) Anti-CTLA4 antibodies
JP7681025B2 (ja) 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
KR20250097987A (ko) Cd40 및 cd137에 대한 다중특이적 항체
JP2023522520A5 (https=)
AU2019217207B2 (en) Improved antagonistic anti-human CD40 monoclonal antibodies
KR20210138033A (ko) 항-Vβ17/항-CD123 이중특이성 항체
AU2014268298A1 (en) Anti-B7-H5 antibodies and their uses
TW202221042A (zh) Pd-1/vegf四價雙特異性抗體、其製備方法和用途
KR20190026766A (ko) 항-il-22r 항체
AU2022301381A1 (en) Anti-cd3 antibody and use thereof
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
JP6800191B2 (ja) 抗ｐｄ−１抗体並びにその治療及び診断のための使用
EA049801B1 (ru) Антитела против hvem человека (tnfrsf14) и их применение
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
HK40112413A (zh) 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途
NZ782254A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
HK1217501B (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
EA044655B1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств